Merck\'s Keytruda sets new fiveyear survival standard for advanced lung cancer

Merck's Keytruda sets new five-year survival standard for advanced lung cancer

Nearly a quarter of patients who received Merck & Co's immunotherapy Keytruda as an initial treatment for advanced lung cancer were still alive after five years, according to data presented at a major medical meeting on Saturday.

More From BioPortfolio on "Merck's Keytruda sets new five-year survival standard for advanced lung cancer"